Childhood leukemia is one of medicine's great success stories — but a new study reveals the treatment journey takes a serious toll on the whole family. Published in the October 2026 issue of JNCCN, the multicenter study followed 420 children being treated for standard-risk B-ALL and found that adverse family outcomes — including household employment changes and shifts in marital status — emerged quickly and persisted throughout the entire ~2.5-year treatment period.

The findings are striking: more than half of families reported at least one major household disruption within just two months of diagnosis, and that number climbed to over 80% by 26 months. Even when treatment intensity was reduced (comparing maintenance chemotherapy given every 4 vs. 12 weeks), family hardship remained largely unchanged — suggesting the burden isn't simply a function of how intensive a child's treatment is.

By the Numbers:

• 56.2% of families reported at least one household change within ~2 months of diagnosis
• 81.2% of families were impacted by 26 months into treatment
• 420 children enrolled across 200+ Children's Oncology Group member institutions
• B-ALL treatment typically lasts ~2.5 years

Why it matters: B-ALL is the most common childhood cancer, and the COG institutions involved treat roughly 80% of all new pediatric cancer cases — meaning these findings reflect the reality for most affected families in the U.S. Experts are calling for routine caregiver screening for financial toxicity and employment disruption, and for multidisciplinary support to be integrated into cancer care from the very start.